BLTE Stock Summary and Trading Ideas (Belite Bio - American Depositary Shares | NASDAQ:BLTE)

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Belite Bio - American Depositary Shares trades on the NASDAQ stock market under the symbol BLTE.

As of November 13, 2026, BLTE stock price declined to $164.35 with 211,107 million shares trading.

BLTE has a beta of 0.87, meaning it tends to be less sensitive to market movements. BLTE has a correlation of 0.06 to the broad based SPY ETF.

BLTE has a market cap of $6.17 billion. This is considered a Mid Cap stock.

In the last 3 years, BLTE traded as high as $200.00 and as low as $31.01.

The top ETF exchange traded funds that BLTE belongs to (by Net Assets): SPEM, APIE, ONEQ, GXC, BBC.

BLTE has outperformed the market in the last year with a price return of +46.2% while the SPY ETF gained +13.4%. BLTE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -1.2% and +6.2%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

BLTE support price is $163.18 and resistance is $176.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLTE shares will trade within this expected range on the day.